Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$13.74 -4.6%	$14.00	$7.86 ▼ $17.75	$1.64B	1.76	2.21 million shs	2.34 million shs
BHC Bausch Health Cos	$6.44 +0.4%	$5.14	$3.96 ▼ $9.85	$2.39B	0.28	2.62 million shs	2.70 million shs
CAPR Capricor Therapeutics	$11.15 +9.5%	$10.88	$3.52 ▼ $23.40	$509.30M	0.84	1.97 million shs	2.64 million shs
SUPN Supernus Pharmaceuticals	$31.16 -0.1%	$32.18	$25.55 ▼ $40.28	$1.74B	0.71	473,795 shs	1.10 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	0.00%	-0.58%	+0.51%	-12.65%	+47.90%
BHC Bausch Health Cos	0.00%	+4.29%	+39.95%	-0.77%	-5.23%
CAPR Capricor Therapeutics	0.00%	+34.99%	+10.51%	-3.04%	+140.82%
SUPN Supernus Pharmaceuticals	0.00%	-3.47%	-1.64%	-3.50%	+16.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	1.973 of 5 stars	3.4	1.0	0.0	2.2	1.7	0.6
BHC Bausch Health Cos	3.8383 of 5 stars	1.9	3.0	4.0	3.3	3.3	0.6
CAPR Capricor Therapeutics	3.2263 of 5 stars	4.6	3.0	0.0	1.8	0.8	0.6
SUPN Supernus Pharmaceuticals	2.2241 of 5 stars	2.2	2.0	4.1	1.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	36.83% Upside
BHC Bausch Health Cos	1.86	Reduce	$7.42	15.26% Upside
CAPR Capricor Therapeutics	3.13	Buy	$33.75	202.69% Upside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	15.53% Upside

Current Analyst Ratings Breakdown

Latest CAPR, ARQT, BHC, and SUPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
6/25/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	CAPR Capricor Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $29.00
6/24/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00
6/23/2025	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$43.00 ➝ $22.00
6/17/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/13/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00
5/23/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/20/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
5/14/2025	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00
5/2/2025	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$8.50 ➝ $10.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$196.54M	8.33	N/A	N/A	$1.35 per share	10.18
BHC Bausch Health Cos	$9.63B	0.25	$7.75 per share	0.83	($0.89) per share	-7.23
CAPR Capricor Therapeutics	$22.27M	22.87	N/A	N/A	$3.20 per share	3.48
SUPN Supernus Pharmaceuticals	$661.82M	2.64	$4.17 per share	7.47	$18.76 per share	1.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$140.04M	-$1.04	N/A	N/A	N/A	-60.95%	-80.66%	-32.94%	8/13/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.38	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
CAPR Capricor Therapeutics	-$40.47M	-$1.42	N/A	N/A	N/A	-181.71%	-62.42%	-48.36%	8/6/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$73.86M	$1.11	28.07	21.64	N/A	9.27%	12.23%	9.17%	8/5/2025 (Estimated)

Latest CAPR, ARQT, BHC, and SUPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.75	3.55	3.37
BHC Bausch Health Cos	N/A	1.35	0.97
CAPR Capricor Therapeutics	N/A	6.55	6.55
SUPN Supernus Pharmaceuticals	N/A	2.44	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
BHC Bausch Health Cos	78.65%
CAPR Capricor Therapeutics	21.68%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
BHC Bausch Health Cos	8.05%
CAPR Capricor Therapeutics	10.50%
SUPN Supernus Pharmaceuticals	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	108.00 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
CAPR Capricor Therapeutics	N/A	45.68 million	40.88 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.99 million	51.06 million	Optionable

CAPR, ARQT, BHC, and SUPN Headlines

Recent News About These Companies

Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions

June 27 at 10:35 PM | msn.com

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years

June 23, 2025 | uk.finance.yahoo.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Hold Rating by Wall Street Zen

June 21, 2025 | marketbeat.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025 | businesswire.com

Supernus Pharma to Buy Sage Therapeutics for Up to $795 Million

June 16, 2025 | marketwatch.com

Supernus enters depression drug market with up to $795 million Sage deal

June 16, 2025 | msn.com

Supernus to acquire depression drugmaker Sage

June 16, 2025 | msn.com

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

June 16, 2025 | msn.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

June 16, 2025 | prnewswire.com

Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal

June 16, 2025 | gurufocus.com

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...

June 16, 2025 | gurufocus.com

Supernus Pharmaceuticals to Acquire Sage Therapeutics in a Strategic Move | SUPN stock news

June 16, 2025 | gurufocus.com

Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.

June 16, 2025 | barrons.com

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...

June 16, 2025 | gurufocus.com

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

June 16, 2025 | reuters.com

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

June 16, 2025 | globenewswire.com

Azzad Asset Management Inc. ADV Acquires New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

June 16, 2025 | marketbeat.com

GAMMA Investing LLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

June 16, 2025 | marketbeat.com

Wedge Capital Management L L P NC Acquires 13,955 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

June 10, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Two Sigma Investments LP

June 7, 2025 | marketbeat.com

Hennion & Walsh Asset Management Inc. Acquires 11,304 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

June 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, ARQT, BHC, and SUPN Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$13.74 -0.66 (-4.58%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.86 +0.13 (+0.91%)

As of 06/27/2025 07:33 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Bausch Health Cos NYSE:BHC

$6.44 +0.03 (+0.39%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$6.51 +0.07 (+1.15%)

As of 06/27/2025 07:21 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Capricor Therapeutics NASDAQ:CAPR

$11.15 +0.97 (+9.53%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.16 +0.00 (+0.04%)

As of 06/27/2025 07:59 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Supernus Pharmaceuticals NASDAQ:SUPN

$31.16 -0.04 (-0.13%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$31.17 +0.01 (+0.03%)

As of 06/27/2025 04:34 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time